Application of an Artificial Neural Network in the Diagnosis of Chronic Lymphocytic Leukemia.

artificial neural network biomarkers chronic lymphocytic leukemia diagnosis

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
04 Feb 2019
Historique:
entrez: 20 4 2019
pubmed: 20 4 2019
medline: 20 4 2019
Statut: epublish

Résumé

Introduction Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia, and the early diagnosis of patients coincides with their proper treatment and survival. If patients are diagnosed late or proper treatment is not applied, it may lead to harmful results. Several methods could be used for the diagnosis of leukemia; some of these include complete blood count (CBC), immunophenotyping, lymph node biopsy, chest X-ray, computerized tomography (CT) scan, and ultrasound. Most of these methods are time-consuming and an application of more than one method will result as intended. This acknowledgment stresses the necessity of rapid and proper diagnosis for leukemia based on clinical and medical findings, inasmuch as it was decided to apply the artificial neural network (ANN) in order to identify a molecular biomarker for rapid leukemia diagnosis from blood samples and evaluate its potential for the detection of cancer. Materials & methods The independent sample t-test was applied with the Statistical Package for the Social Sciences (SPSS; IBM Corp, Armonk, NY, US) software on the microarray gene expression data of Gene Expression Omnibus (GEO) datasets (GSE22529); 12 genes that had shown the highest differences (among parameters whose p-value was less than 0.01) were selected for further ANN analysis. The selected genes of 53 patients were applied to the training network algorithm, with a learning rate of 0.1. Results The results showed a high accuracy of the relationship between the output of the trained network and the test data. The area under the receiver operating characteristic (ROC) curve was 0.991, which provides proof of the precision and the relationship with identifying Gelsolin as a potential biomarker for this research. Conclusions With these results, it was concluded that the training process of the ANN could be applied to rapid CLL diagnosis and finding a potential biomarker. Besides, it is suggested that this method could be performed to diagnose other forms of cancer in order to get a rapid and reliable outcome.

Identifiants

pubmed: 31001458
doi: 10.7759/cureus.4004
pmc: PMC6450593
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e4004

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Blood. 1999 Sep 15;94(6):1848-54
pubmed: 10477713
J Biol Chem. 1999 Nov 19;274(47):33179-82
pubmed: 10559185
Semin Oncol. 1999 Oct;26(5 Suppl 14):107-14
pubmed: 10561025
Nat Med. 2001 Jun;7(6):673-9
pubmed: 11385503
J Clin Oncol. 2002 Feb 15;20(4):921-9
pubmed: 11844812
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9
pubmed: 12434020
N Engl J Med. 2003 May 1;348(18):1777-85
pubmed: 12724484
Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60
pubmed: 15284443
Comput Biol Chem. 2005 Feb;29(1):37-46
pubmed: 15680584
N Engl J Med. 2005 Feb 24;352(8):804-15
pubmed: 15728813
Blood. 2008 Jun 15;111(12):5446-56
pubmed: 18216293
BMC Bioinformatics. 2008 Jul 22;9:319
pubmed: 18647401
Asian Pac J Cancer Prev. 2011;12(11):2991-4
pubmed: 22393977
J Res Med Sci. 2013 Apr;18(4):363-5
pubmed: 24124438
Genomics. 2015 Dec;106(6):360-6
pubmed: 26520014
Iran Biomed J. 2018 Jul 30;23(3):175-83
pubmed: 30056689
Nature. 1987 Jan 22-28;325(6102):362-4
pubmed: 3027569
Int J Hematol Oncol. 2017 Dec;6(4):105-111
pubmed: 30302231
Cancer. 1981 Jul 1;48(1):198-206
pubmed: 7237385
Science. 1995 Oct 20;270(5235):467-70
pubmed: 7569999
N Engl J Med. 1995 Oct 19;333(16):1052-7
pubmed: 7675049
Nature. 1993 Aug 19;364(6439):685-92
pubmed: 8395021
Radiology. 1993 Apr;187(1):81-7
pubmed: 8451441
Cancer. 1997 Feb 15;79(4):857-62
pubmed: 9024725

Auteurs

Fateme Shaabanpour Aghamaleki (F)

Genetics, Shahid Beheshti University of Medical Sciences, Tehran, IRN.

Behrouz Mollashahi (B)

Genetics, Shahid Beheshti University of Medical Sciences, Tehran, IRN.

Mokhtar Nosrati (M)

Genetics, University of Isfahan, Isfahan, IRN.

Afshin Moradi (A)

Pathology, Shahid Beheshti University of Medical Science, Tehran, IRN.

Mojgan Sheikhpour (M)

Genetics, Pasteur Institute of Iran, Tehran, IRN.

Abolfazl Movafagh (A)

Genetics, Shahid Beheshti University of Medical Sciences, Tehran, IRN.

Classifications MeSH